GAITHERSBURG, Md., Aug. 11,
2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a
biotechnology company dedicated to developing and commercializing
next-generation vaccines for serious infectious diseases, today
announced that it will participate in a fireside chat during the
SVB Securities Virtual Vaccine Forum. Novavax' recombinant
nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373,
will be a topic of discussion.
Fireside chat
details:
|
|
Date:
|
Thursday, August 18,
2022
|
|
Time:
|
11:00 – 11:50 a.m.
Eastern Daylight Time (EDT)
|
|
Moderator:
|
David Risinger,
CFA
|
|
Novavax
participants:
|
Filip Dubovsky, M.D.,
Executive Vice President, Chief Medical Officer and John J.
Trizzino, Executive Vice President, Chief Commercial Officer and
Chief Business Officer
|
|
|
|
|
|
Please contact your SVB Securities representative to view the
session.
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that
promotes improved health globally through the discovery,
development, and commercialization of innovative vaccines to
prevent serious infectious diseases. The company's proprietary
recombinant technology platform harnesses the power and speed of
genetic engineering to efficiently produce highly immunogenic
nanoparticles designed to address urgent global health needs. The
Novavax COVID-19 vaccine, has received authorization from multiple
regulatory authorities globally, including the U.S., European
Commission and the WHO. The vaccine is currently under review by
multiple regulatory agencies worldwide, including for additional
indications and populations such as adolescents and as a booster.
In addition to its COVID-19 vaccine, Novavax is also currently
evaluating a COVID-seasonal influenza combination vaccine candidate
in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and
NanoFlu*, its quadrivalent influenza investigational vaccine
candidate, and is also evaluating an Omicron strain-based vaccine
(NVX-CoV2515) as well as a bivalent format Omicron-based / original
strain-based vaccine. These vaccine candidates incorporate Novavax'
proprietary saponin-based Matrix-M adjuvant to enhance the immune
response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect
with us on LinkedIn.
*NanoFlu identifies a recombinant hemagglutinin (HA) protein
nanoparticle influenza vaccine candidate produced by Novavax. This
investigational candidate was evaluated during a controlled phase 3
trial conducted during the 2019-2020 influenza season.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com
Media
Ali Chartan | 240-720-7804
Laura Keenan Lindsey |
202-709-7521
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-fireside-chat-at-the-svb-securities-virtual-vaccine-forum-301604557.html
SOURCE Novavax, Inc.